The FDA named Dexcom its first TEMPO participant, allowing digital health devices to reach Medicare patients before authorisation in exchange for real-world data.
I’m glad you got some feedback out of it. I think that’s where they have the most value right now. But they are too expensive and too inconsistent for the sort of mass rollout RFK wants here in the US. They need to improve a lot to move away from the style of use you got out of an OTC version.
I’m glad you got some feedback out of it. I think that’s where they have the most value right now. But they are too expensive and too inconsistent for the sort of mass rollout RFK wants here in the US. They need to improve a lot to move away from the style of use you got out of an OTC version.